Clarus Therapeutics Holdings, Inc.
CRXTDelisted Sep 14, 2022- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001817944
Clarus Therapeutics Holdings, Inc. was delisted on Sep 14, 2022; its insiders filed their last Form 4 on Jun 9, 2022; 25 institutions reported holding it in 13F filings for Q2 2022, worth $1.82M in total; no superinvestor held it.
13F holders, Q2 2022
Institutional positions in Clarus Therapeutics Holdings, Inc. as of Jun 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 25
- +12 vs. Q1 2022
- Shares held
- 4.78M
- +2.28M (+91.0%) vs. Q1 2022
- Total value
- $1.82M
- −$1.91M (−51.2%) vs. Q1 2022
- New holders
- 13
- 8 more added
- Sold out
- 1
- 3 more reduced
Compare with Q1 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CRXT on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 1 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 0 | $0 |
| Q3 2024 | 0 | $0 |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 0 | $0 |
| Q4 2023 | 0 | $0 |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 2 | $5.00K |
| Q2 2022 | 25 | $1.82M |
| Q1 2022 | 13 | $3.73M |
| Q4 2021 | 12 | $10.5M |
| Q3 2021 | 12 | $12.1M |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2022
Shares, value and share of portfolio for each institution holding Clarus Therapeutics Holdings, Inc.; share changes are against Q1 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Bracebridge Capital, LLC | 2,002,495 | $761.0K | 0.25% | 00.0% | Unchanged |
| Vanguard Group Inc | 1,039,148 | $397.0K | 0.00% | +864,648+495.5% | Added |
| BlackRock Inc. | 323,800 | $124.0K | 0.00% | +323,800 | New |
| Geode Capital Management, LLC | 301,652 | $115.0K | 0.00% | +267,737+789.4% | Added |
| Sabby Management, LLC | 200,000 | $76.0K | 0.14% | +200,000 | New |
| Virtu Financial LLC | 188,086 | $72.0K | 0.01% | +167,733+824.1% | Added |
| Millennium Management LLC | 170,520 | $65.0K | 0.00% | +131,292+334.7% | Added |
| Renaissance Technologies LLC | 122,277 | $47.0K | 0.00% | +87,577+252.4% | Added |
| Cetera Advisor Networks LLC | 63,000 | $24.0K | 0.00% | +63,000 | New |
| Powell Investment Advisors, LLC | 60,000 | $23.0K | 0.01% | +60,000 | New |
| Warberg Asset Management LLC | 55,000 | $21.0K | 0.01% | +55,000 | New |
| Bridgeway Capital Management, LLC | 45,000 | $17.0K | 0.00% | −45,000−50.0% | Reduced |
| Ayrton Capital LLC | 32,525 | $12.0K | 0.02% | +32,525 | New |
| Verition Fund Management LLC | 30,004 | $11.0K | 0.00% | +40.0% | Added |
| Squarepoint Ops LLC | 29,085 | $11.0K | 0.00% | +29,085 | New |
| State Street Corp | 25,536 | $10.0K | 0.00% | +25,536 | New |
| UBS Group AG | 23,534 | $9.00K | 0.00% | −43,003−64.6% | Reduced |
| Citigroup Inc | 18,000 | $7.00K | 0.00% | +10,600+143.2% | Added |
| StoneX Group Inc. | 11,685 | $4.46K | 0.00% | +11,685 | New |
| Two Sigma Investments, LP | 10,001 | $4.00K | 0.00% | +10,001 | New |
| Advisor Group Holdings, Inc. | 10,000 | $4.00K | 0.00% | +10,000 | New |
| Wealthcare Advisory Partners LLC | 11,578 | $4.00K | 0.00% | +11,578 | New |
| Morgan Stanley | 6,957 | $3.00K | 0.00% | +6,957 | New |
| Tower Research Capital LLC (TRC) | 620 | $0 | 0.00% | −3,316−84.2% | Reduced |
| Wells Fargo & Company | 230 | $0 | 0.00% | +190+475.0% | Added |
| Royal Bank of Canada | 0 | $0 | 0.00% | −500−100.0% | Sold out |